We have demonstrated success with a proven track record of multiple successful biosimilar approvals in the U.S., Europe and several other advanced and emerging market countries. Biocon Biologics has many firsts to its credit, including the industry’s first approval of an interchangeable biosimilar, for Insulin Glargine in the U.S. We are also the first globally to receive approvals for biosimilar Trastuzumab and biosimilar Pegfilgrastim from the U.S. Food and Drug Administration (FDA).

Our 20 ‘in-market’ and ‘in-development’ biosimilars can potentially address a USD 78 billion [1] global market opportunity by FY28. Of these, eight [2] biosimilars have been commercialized in global markets and are making a difference to the lives of ~ 5.5 million patients annually.

A frontrunner in the global biosimilars industry, Biocon Biologics has over the past two decades invested over USD 1 billion in building dedicated ‘lab to market’ capabilities for biosimilars. This has led to the creation of state-of-the-art R&D facilities in India and large scale, globally compliant manufacturing infrastructure in India and Malaysia. We have also invested in high-end quality processes and technology to meet global quality standards and achieve regulatory compliance, in India as well as internationally. To take our biosimilars to patients we have expanded our commercial footprint to over 100 countries through a combination of direct presence, strategic partnerships and distributor tie-ups.

To strengthen its leadership position in the global biosimilars industry, Biocon Biologics has acquired the global biosimilars business of our long-term partner Viatris for over USD 3 billion in cash and stock. This is a historic milestone in our value creation journey and brings us closer to patients, customers, and payors in several advanced and emerging market countries.

Besides a robust biosimilars franchise, Biocon Biologics also has a strategic alliance with Serum Institute Life Sciences for vaccines (subject to regulatory approvals and closure of the transaction) to address the inequitable access to lifesaving vaccines worldwide.

[1] Global MAT Q3’CY22 sales are used as base data.
[2] Includes in-licensed programs (bAdalimumab and bEtanercept)

Unique Biosimilars portfolio spanning rh-insulin, insulin analogs, monoclonal antibodies and conjugated recombinant proteins.

8 biosimilars commercialized in markets globally – Trastuzumab, Pegfilgrastim, Bevacizumab, rh-Insulin, Insulin Glargine, Insulin Aspart,Adalimumab^#, Etanercept^#.

~7.3 billion doses of insulins  provided to patients globally since 2004.

~5.5 million* patients reached through our products (MAT March 2024)*

Cutting-edge science & research capabilities, resulting in several global ‘firsts’ in the biosimilars industry.

Among the Top 15 global  biopharma players in terms of bio-manufacturing capacity.

High standards of quality & compliance. 25+ cGMP approvals from  international regulatory agencies.

~6,500+ people  dedicated to support this business across various functions.

# In-licensed molecules
* Number of patients is calculated based on volume supplied